Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:January 22, 2024Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Multiple MyelomaLast Updated:January 22, 2024Not yet recruiting
Condition(s):Lymphoma; Multiple Myeloma; Non-Hodgkin Lymphoma; Relapsed Hodgkin’s Disease, AdultLast Updated:February 2, 2024Recruiting
Condition(s):Antibody-mediated Rejection; AllosensitizationLast Updated:February 26, 2024Not yet recruiting
Condition(s):Monoclonal GammopathyLast Updated:March 6, 2024Recruiting
Condition(s):Immune System DisorderLast Updated:June 27, 2023Terminated
Condition(s):Plasma Cell MyelomaLast Updated:March 8, 2024Active, not recruiting
Condition(s):LymphomaLast Updated:October 17, 2023Terminated
Condition(s):Multiple MyelomaLast Updated:September 8, 2023Completed
Condition(s):Prostate Cancer; Non-small Cell Lung CancerLast Updated:May 16, 2022Terminated
Condition(s):Plasma Cell MyelomaLast Updated:April 19, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.